Skip to main content Back to Top
Advertisement

7/23/2019

Methyldopa Tablets

Products Affected - Description

    • Methyldopa oral tablet, Accord, 250 mg, bottle, 500 count, NDC 16729-0030-16
    • Methyldopa oral tablet, Accord, 500 mg, bottle, 500 count, NDC 16729-0031-16

Reason for the Shortage

    • Accord has methyldopa tablets available.
    • Mylan refuses to provide availability information.
    • Teva discontinued methyldopa tablets in 2018.

Available Products

    • Methyldopa oral tablet, Accord, 250 mg, bottle, 100 count, NDC 16729-0030-01
    • Methyldopa oral tablet, Accord, 500 mg, bottle, 100 count, NDC 16729-0031-01

Estimated Resupply Dates

    • Accord has methyldopa 250 mg tablets in 500 count on back order and the company estimates a release date of late-August 2019. The 500 mg tablets in 500 count are on back order and the company estimates a release date of late-July 2019.

Updated

Updated July 23, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created August 28, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins